NASDAQ:BIAF bioAffinity Technologies - BIAF Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.78 -0.09 (-3.14%) (As of 01/30/2023 03:36 PM ET) Add Compare Share Share Today's Range$2.63▼$3.0650-Day Range$1.52▼$3.0652-Week Range$1.31▼$15.55Volume234,629 shsAverage Volume4.13 million shsMarket Capitalization$7.59 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media About bioAffinity Technologies (NASDAQ:BIAF) StockbioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.Read More Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address BIAF Stock News HeadlinesJanuary 24, 2023 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.31%January 24, 2023 | seekingalpha.comBIAF bioAffinity Technologies, Inc.January 30, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 24, 2023 | finance.yahoo.combioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory ResearchJanuary 4, 2023 | finance.yahoo.combioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer TreatmentsDecember 19, 2022 | finance.yahoo.comArgus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)December 15, 2022 | finance.yahoo.combioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical BenchNovember 8, 2022 | finance.yahoo.combioAffinity Technologies to Report Third Quarter 2022 Financial ResultsJanuary 30, 2023 | Investing Trends (Ad)"We need batteries. Literally everywhere."Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense." November 2, 2022 | bizjournals.comSan Antonio cancer biotech follows IPO with patent win in ChinaOctober 13, 2022 | wsj.combioAffinity Technologies Inc.September 30, 2022 | bizjournals.comBehind the Deal: Company’s decision to go public drawing capital and attention to SASeptember 29, 2022 | markets.businessinsider.comNasdaq Surges Over 150 Points; Gold Rises 2%September 14, 2022 | msn.comWhy BioAffinity Technologies Shares Are SkyrocketingSeptember 14, 2022 | baystreet.caBioAffinity Publishes Peer ResultsSeptember 14, 2022 | nasdaq.comBioAffinity Technologies Shares SpikeSeptember 10, 2022 | investing.combioAffinity Technologies Inc (BIAF)September 9, 2022 | bizjournals.comSan Antonio biotech goes public raising nearly $8MSeptember 6, 2022 | reuters.combioAffinity Technologies IncSeptember 6, 2022 | finance.yahoo.combioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public OfferingSeptember 6, 2022 | finance.yahoo.comWallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public OfferingSeptember 2, 2022 | ca.finance.yahoo.combioAffinity Technologies, Inc. (BIAF)September 2, 2022 | investing.combioAffinity Technologies IPO Opens Sharply HigherSeptember 2, 2022 | seekingalpha.comLung cancer test developer bioAffinity prices $8M IPOSeptember 2, 2022 | seekingalpha.comBioAffinity stock soars over 150% following $8M IPOSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BIAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address BIAF Company Calendar Last Earnings11/14/2022Today1/30/2023Next Earnings (Estimated)9/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIAF CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.60 Quick Ratio9.60 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,730,000Free FloatN/AMarket Cap$7.59 million OptionableNot Optionable BetaN/A Key ExecutivesMs. Maria Zannes J.D. (Age 67)Founder, Pres, CEO & Director Comp: $227.2kDr. Vivienne I. Rebel M.D. (Age 58)Ph.D., Exec. VP and Chief Medical & Science Officer Comp: $236.59kMr. Michael Edwards CPA (Age 56)M.B.A., Chief Financial Officer Mr. Xavier T. Reveles M.S.VP of OperationsMr. Timothy P. Zannes J.D. (Age 70)Exec. VP, Sec. & Gen. Counsel Dr. William Bauta Ph.D.Sr. VP of TherapeuticsMore ExecutivesKey CompetitorsiSpecimenNASDAQ:ISPCAdvaxisNASDAQ:ADXSNovo Integrated SciencesNASDAQ:NVOSHistogenNASDAQ:HSTOAllied Healthcare ProductsNASDAQ:AHPIView All CompetitorsInsiders & InstitutionsJane Street Group LLCBought 11,004 shares on 11/16/2022Ownership: 0.403%Citadel Advisors LLCBought 20,583 shares on 11/15/2022Ownership: 0.754%View All Institutional Transactions BIAF Stock - Frequently Asked Questions How have BIAF shares performed in 2023? bioAffinity Technologies' stock was trading at $1.60 at the beginning of the year. Since then, BIAF shares have increased by 73.8% and is now trading at $2.78. View the best growth stocks for 2023 here. When is bioAffinity Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, September 1st 2023. View our BIAF earnings forecast. How were bioAffinity Technologies' earnings last quarter? bioAffinity Technologies, Inc. (NASDAQ:BIAF) posted its quarterly earnings results on Monday, November, 14th. The company reported ($1.10) EPS for the quarter. When did bioAffinity Technologies IPO? (BIAF) raised $8 million in an IPO on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager. What is bioAffinity Technologies' stock symbol? bioAffinity Technologies trades on the NASDAQ under the ticker symbol "BIAF." When does bioAffinity Technologies' lock-up period expire? bioAffinity Technologies' lock-up period expires on Tuesday, February 28th. bioAffinity Technologies had issued 1,282,600 shares in its public offering on September 1st. The total size of the offering was $7,862,338 based on an initial share price of $6.13. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period. How do I buy shares of bioAffinity Technologies? Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is bioAffinity Technologies' stock price today? One share of BIAF stock can currently be purchased for approximately $2.78. How much money does bioAffinity Technologies make? bioAffinity Technologies (NASDAQ:BIAF) has a market capitalization of $7.59 million. How can I contact bioAffinity Technologies? The official website for the company is www.bioaffinitytech.com. The company can be reached via email at jnugent@tiberend.com. This page (NASDAQ:BIAF) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.